Optimization of antiretroviral therapy in HIV-infected children under 3 years of age: A systematic review

AIDS

Volumn 28, Issue SUPPL. 2, 2014, Pages

  Penazzato, Martina ^a,b   Prendergast, Andrew J ^a,c,d   Muhe, Lulu M ^b   Tindyebwa, Denis ^e   Abrams, Elaine J ^f  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^d Zvitambo Institute for Maternal and Child Health Research   (Zimbabwe)

^e African Network for the Care of Children Affected by HIV/AIDS (ANECCA)   (Uganda)

^f Mailman School of Public Health College of Physicians and Surge Columbia University ^*  (United States)

Author keywords

antiretroviral therapy; children; HIV infection; infants; randomized controlled trial; systematic review

Indexed keywords

LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; ANTIRETROVIRUS AGENT;

ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ASYMPTOMATIC INFECTION; CHILDHOOD DISEASE; DISEASE COURSE; DISEASE TRANSMISSION; DRUG SUBSTITUTION; GROUPS BY AGE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; INFANT DISEASE; INFANT MORTALITY; INFECTION RISK; MAINTENANCE THERAPY; META ANALYSIS; MORBIDITY; OUTCOME ASSESSMENT; PREVENTION OF MOTHER TO CHILD TRANSMISSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT FAILURE; VIRUS LOAD; VIRUS TRANSMISSION; WORLD HEALTH ORGANIZATION; HIV INFECTIONS; IMMUNOLOGY; INFANT; MORTALITY; PRESCHOOL CHILD; PREVENTION AND CONTROL; TRANSMISSION; TREATMENT OUTCOME; VERTICAL TRANSMISSION;

ANTI-RETROVIRAL AGENTS; CHILD, PRESCHOOL; DISEASE PROGRESSION; HIV INFECTIONS; HUMANS; INFANT; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901410380     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000240     Document Type: Review

References (34)

1. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, Dabis F. Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 2004; 364:1236-1243.
2. Gibb DM, Giaquinto C. Children with HIV infection: special cases. Lancet 2000; 356 (Suppl):s34.
3. 2013 UNAIDS Report on the Global AIDS Epidemic. UNAIDS, 2013. Available at http://www.unaids.org/en/resources/docu ments/2013/name,85053,en.asp.
4. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2013, www.who.int/hiv/pub/guidelines/arv2013. [Accessed 26 January 2014]
5. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: towards universal access: recommendations for a public health approach. [2010 revision]. Geneva: World Health Organization; 2010, http://whqlibdoc.who.int/publications/2010/ 9789241599818-eng.pdf. [Accessed 26 January 2014]
6. Arpadi S, Shiau S, Strehlau R, Martens L, Patel F, Coovadia A, et al. Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy. Arch Dis Child 2013; 98:258-264.
7. Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, et al. Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in Sub-Saharan Africa: a cohort-based modelling study. PLoS Med 2013; 10:e1001542.
8. Prendergast AJ, Penazzato M, Cotton M, Musoke P, Mulenga V, Abrams EJ, et al. Treatment of young children with HIV infection: using evidence to inform policymakers. PLoS Med 2012; 9:e1001273.
9. Arrive E, Newell ML, Ekouevi DK, Chaix ML, Thiebaut R, Masquelier B, et al. Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. Int J Epidemiol 2007; 36:1009-1021.
10. Martinson NA, Morris L, Gray G, Moodley D, Pillay V, Cohen S, et al. Selection and persistence of viral resistance in HIVinfected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr 2007; 44:148-153.
11. Church JD, Mwatha A, Bagenda D, Omer SB, Donnell D, Musoke P, et al. In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses 2009; 25:673-677.
12. Lockman S, Shapiro RL,SmeatonLM,Wester C, Thior I, Stevens L, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med 2007; 356:135-147.
13. Musiime V, Ssali F, Kayiwa J, Namala W, Kizito H, Kityo C, et al. Response to nonnucleoside reverse transcriptase inhibitorbased therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. AIDS Res Hum Retroviruses 2009; 25:989-996.
14. Penazzato M, Prendergast AJ, Muhe LM, Tindyebwa D, Abrams EJ. Optimisation of antiretroviral therapy in HIVinfected children under 3 years of age. Cochrane Database Syst Rev 2014; 3:(in press).
15. National Institute of Allergy and infectious Diseases (NIAID) NUSNIoAaID. Division of AIDS table for grading the severity of adult and pediatric adverse events. 2004. http://www.niaid.nih. gov/LabsAndResources/resources/ DAIDSClinRsrch/Documents/daidsaegradingtable.pdf. [Accessed 20 February 2014]
16. Higgins J, Green S. Cochrane handbook for systematic reviews of interventions, version 5.1.0. March 2011.
17. Violari A, Cotton MF, Gibb DM, Babiker AG, Steyn J, Madhi SA, et al. Early antiretroviral therapy and mortality among HIVinfected infants. N Engl J Med 2008; 359:2233-2244.
18. Coovadia A, Abrams EJ, Stehlau R, Meyers T, Martens L, Sherman G, et al. Reuse of nevirapine in exposed HIVinfected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010; 304:1082-1090.
19. Palumbo P, Lindsey JC, Hughes MD, Cotton MF, Bobat R, Meyers T, et al. Antiretroviral treatment for children with peripartum nevirapine exposure. N Engl J Med 2010; 363: 1510-1520.
20. Violari A, Lindsey JC, Hughes MD, Mujuru HA, Barlow-Mosha L, Kamthunzi P, et al. Nevirapine versus ritonavir-boosted lopinavir for HIV-infected children. N Engl J Med 2012; 366: 2380-2389.
21. Kekitiinwa A, Cook A, Nathoo K, Mugyenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet 2013; 381:1391-1403.
22. Wamalwa DB-NS, Langat A, Tapia K, Ngugi E, Moraa H, Otieno V, et al. Treatment interruption in infants following 24 months of empiric ART: Kenya. 19th Conference on Retroviruses and Opportunistic Infections; 5-8 March 2012; Seattle, WA.
23. Ruel TKA, Ikilezi G, Mwangwa F, Dorsey G, Rosenthal P, Charlebois E, et al. Comparison of virologic and immunologic outcomes between HIVR Ugandan children randomized to ritonavir-boosted lopinavir or NNRTI-based ART [Abstract 88 LB]. 20th Conference on Retroviruses and Opportunistic Infections; 3-6 March 2013; Atlanta, GA.
24. Prendergast A, Tudor-Williams G, Mphatswe W, Cengimbo A, Thobakgale C, Dong C, et al. Randomized controlled trial of 3 approaches to management of HIV-infected infants [Abstract 77LB]. 16th Conferences on Retroviruses and Opportunistic Infections; 3-6 February 2008; Boston, MA.
25. Prendergast A, Mphatswe W, Tudor-Williams G, Rakgotho M, Pillay V, Thobakgale C, et al. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants. AIDS 2008; 11:1333-1343.
26. Department of Health and Human Services. Antiretroviral Therapy and Medical Management of HIV-Infected Children. 2013. http://aidsinfo.nih.gov/ guidelines/html/2/pediatric-arvguidelines/0. [Accessed 20 February 2014]
27. Welch S, Sharland M, Lyall EG, Tudor-Williams G, Niehues T, Wintergerst U, et al. PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Med 2009; 10:591-613.
28. Chatterjee A, Bosch RJ, Kupka R, Hunter DJ, Msamanga GI, Fawzi WW. Predictors and consequences of anaemia among antiretroviral-naive HIV-infected and HIV-uninfected children in Tanzania. Public Health Nutr 2010; 13:289-296.
29. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M Jr, Chun TW, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med 2013; 369:1828-1835.
30. Puthanakit T, Saphonn V, Ananworanich J, Kosalaraksa P, Hansudewechakul R, Vibol U, et al. Early versus deferred antiretroviral therapy for children older than 1 year infected with HIV (PREDICT): a multicentre, randomised, open-label trial. Lancet Infect Dis 2012; 12:933-941.
31. Schomaker M, Egger M, Ndirangu J, Phiri S, Moultrie H, Technau K, et al. When to start antiretroviral therapy in children aged 2-5 years: a collaborative causal modelling analysis of cohort studies from southern Africa. PLoS Med 2013; 10:e1001555.
32. Kuhn LHG, Technau K, Coovadia A, Black V, Morris L, Abrams E. Finding infants with HIV Disease and Evaluating Resistance Study Group. Pretreatment drug resistance mutations among HIVR children
33. Apollo TZS, Dzangare J, Chakanyuka C, Mugurungi O, Penazzato M, Martin E, et al. World Health Organization HIV Drug Resistance surveillance in children less than 18 months newly diagnosed with HIV in Zimbabwe. 7th IAS Conference in HIV pathogenesis treatment and prevention; 30 June-3 July 2013; Kuala Lumpur, Malaysia.
34. Cotton MF, Violari A, Otwombe K, Panchia R, Dobbels E, Rabie H, et al. Early time-limited antiretroviral therapy versus deferred therapy in South African infants infected with HIV: results from the children with HIV early antiretroviral (CHER) randomised trial. Lancet 2013; 382:1555-1563.